Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.

PMID: 30227064 · 2016

L, i, q, i, n, g, , W, a, n, g, ;, , H, a, n, g, , Z, h, e, n, g, ;, , X, i, a, o, h, o, n, g, , R, e, n, ;, , H, e, , S, u, n

RevistaTherapeutic innovation & regulatory science
Año2016
PMID30227064

Resumen

The US Food and Drug Administration (FDA) is responsible for protecting public health. Issuance of a warning letter is the FDA's principal means of achieving prompt voluntary compliance with regulations. The objective of this study is to analyze the trends of warning letters issued to medical products about current good manufacturing practices (CGMP) violations during 2007-2014, with a secondary purpose of providing suggestions to manufacturers on how to avoid warning letters. Warning letters we

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑